Literature DB >> 1423494

Pituitary adenylate cyclase-activating polypeptide (PACAP): occurrence in rodent pancreas and effects on insulin and glucagon secretion in the mouse.

T Fridolf1, F Sundler, B Ahrén.   

Abstract

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a neuropeptide that occurs in several tissues, e.g., in the gut. We have studied PACAP-like immunoreactivity in the pancreas of rat and mouse, and the effects of PACAP-38 on basal and stimulated insulin and glucagon secretion in the mouse. Immunofluorescence staining demonstrated the presence of PACAP-like immunoreactivity in nerve fibers in both the rat and mouse pancreas. The nerve fibers were seen in the exocrine pancreas and surrounding the islets. Occasionally, the nerve fibers occurred within the islets. Most PACAP-positive nerve fibers innervated the intrapancreatic ganglia, although no nerve cell bodies contained PACAP-like immunoreactivity. In-vivo experiments in mice revealed that basal plasma glucagon levels were increased by PACAP-38 injected intravenously at dose levels exceeding 1.8 nmol/kg. Furthermore, PACAP-38 (7 nmol/kg) potentiated the plasma glucagon response to the cholinergic agonist carbachol (0.16 mumol/kg). This potentiation was reduced to simple addition by pretreatment with a combined alpha- and beta-adrenergic blockade by phentolamine (35 mumol/kg) and propranolol (8.5 mumol/kg). Moreover, PACAP-38 inhibited a carbachol-induced increase in the level of plasma insulin in the absence but not in the presence of adrenergic blockade. PACAP-38 increased basal plasma insulin levels and increased basal plasma glucose levels 6 min and 10 min, respectively, after injection of the peptide. We conclude that PACAP-like immunoreactivity exists in nerve fibers innervating the mouse and rat pancreas, particularly the intrapancreatic ganglia, and that PACAP-38 augments both basal and carbachol-stimulated glucagon secretion in the mouse.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1423494     DOI: 10.1007/bf00319618

Source DB:  PubMed          Journal:  Cell Tissue Res        ISSN: 0302-766X            Impact factor:   5.249


  18 in total

1.  Enzymatic microdetermination of glycogen.

Authors:  M L Bruss; A L Black
Journal:  Anal Biochem       Date:  1978-01       Impact factor: 3.365

2.  Effects of selective and non-selective beta-adrenergic agents on insulin secretion in vivo.

Authors:  B Ahrén; I Lundquist
Journal:  Eur J Pharmacol       Date:  1981-04-24       Impact factor: 4.432

3.  Effects of helodermin and VIP on insulin and glucagon secretion in the mouse.

Authors:  B Ahrén; B Falck
Journal:  Regul Pept       Date:  1991-01-01

4.  Presence of helodermin-like peptides of the VIP-secretin family in mammalian salivary glands and saliva.

Authors:  P Robberecht; P De Neef; A Vandermeers; M C Vandermeers-Piret; M Svoboda; S Meuris; J De Graef; M C Woussen-Colle; C Yanaihara; N Yanaihara
Journal:  FEBS Lett       Date:  1985-10-07       Impact factor: 4.124

5.  Pituitary adenylate cyclase activating peptide: a novel vasoactive intestinal peptide-like neuropeptide in the gut.

Authors:  F Sundler; E Ekblad; A Absood; R Håkanson; K Köves; A Arimura
Journal:  Neuroscience       Date:  1992       Impact factor: 3.590

6.  Reflex adrenergic control of endocrine pancreas evoked by unloading of carotid baroreceptors in cats.

Authors:  J Järhult; J J Holst
Journal:  Acta Physiol Scand       Date:  1978-10

7.  Pituitary adenylate cyclase activating polypeptide stimulates insulin release from the isolated perfused rat pancreas.

Authors:  K Kawai; C Ohse; Y Watanabe; S Suzuki; K Yamashita; S Ohashi
Journal:  Life Sci       Date:  1992       Impact factor: 5.037

8.  Pituitary adenylate cyclase-activating peptide (PACAP), a new vasoactive intestinal peptide (VIP)-like peptide in the respiratory tract.

Authors:  R Uddman; A Luts; A Arimura; F Sundler
Journal:  Cell Tissue Res       Date:  1991-07       Impact factor: 5.249

9.  Characterization and distribution of binding sites for the hypothalamic peptide, pituitary adenylate cyclase-activating polypeptide.

Authors:  P E Gottschall; I Tatsuno; A Miyata; A Arimura
Journal:  Endocrinology       Date:  1990-07       Impact factor: 4.736

10.  Studies on antibody production. I. A method for the histochemical demonstration of specific antibody and its application to a study of the hyperimmune rabbit.

Authors:  A H COONS; E H LEDUC; J M CONNOLLY
Journal:  J Exp Med       Date:  1955-07-01       Impact factor: 14.307

View more
  18 in total

Review 1.  Trophic effects of PACAP on pancreatic islets: a mini-review.

Authors:  Yusuke Sakurai; Norihito Shintani; Atsuko Hayata; Hitoshi Hashimoto; Akemichi Baba
Journal:  J Mol Neurosci       Date:  2010-07-20       Impact factor: 3.444

2.  Effects of intrathecal administration of pituitary adenylate cyclase activating polypeptide on lower urinary tract functions in rats with intact or transected spinal cords.

Authors:  Mitsuharu Yoshiyama; William C de Groat
Journal:  Exp Neurol       Date:  2008-03-07       Impact factor: 5.330

3.  Pituitary adenylate cyclase-activating polypeptide induces the voltage-independent activation of inward membrane currents and elevation of intracellular calcium in HIT-T15 insulinoma cells.

Authors:  C A Leech; G G Holz; J F Habener
Journal:  Endocrinology       Date:  1995-04       Impact factor: 4.736

Review 4.  Pituitary adenylate cyclase-activating polypeptide and islet amyloid polypeptide in primary sensory neurons: functional implications from plasticity in expression on nerve injury and inflammation.

Authors:  H Mulder; H Jongsma; Y Zhang; S Gebre-Medhin; F Sundler; N Danielsen
Journal:  Mol Neurobiol       Date:  1999-06       Impact factor: 5.590

5.  PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance.

Authors:  F Jamen; K Persson; G Bertrand; N Rodriguez-Henche; R Puech; J Bockaert; B Ahrén; P Brabet
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

6.  Specific antibody recognition of rat pituitary adenylate cyclase activating polypeptide receptors.

Authors:  M Li; S Shioda; A Somogyvári-Vigh; H Onda; A Arimura
Journal:  Endocrine       Date:  1997-10       Impact factor: 3.633

7.  Intra-islet PACAP protects pancreatic β-cells against glucotoxicity and lipotoxicity.

Authors:  Masanori Nakata; Norihito Shintani; Hitoshi Hashimoto; Akemichi Baba; Toshihiko Yada
Journal:  J Mol Neurosci       Date:  2010-05-12       Impact factor: 3.444

8.  Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes.

Authors:  Bilal A Omar; Liu Liehua; Yuchiro Yamada; Yutaka Seino; Piero Marchetti; B Ahrén
Journal:  Diabetologia       Date:  2014-06-18       Impact factor: 10.122

9.  Comparative effects of PACAP and VIP on pancreatic endocrine secretions and vascular resistance in rat.

Authors:  G Bertrand; R Puech; Y Maisonnasse; J Bockaert; M M Loubatières-Mariani
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

10.  Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells.

Authors:  N Inagaki; H Yoshida; M Mizuta; N Mizuno; Y Fujii; T Gonoi; J Miyazaki; S Seino
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.